Smith Sam S, Edwards Luke, Wigmore Timothy, Jhanji Shaman, Antcliffe David B, Tatham Kate C
Division of Anaesthetics, Pain Medicine and Intensive Care, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
Department of Critical Care & Anaesthetics, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
J Intensive Care Med. 2025 Jun;40(6):642-650. doi: 10.1177/08850666241312621. Epub 2025 Jan 28.
IntroductionSepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Patients with cancer are at risk of developing sepsis and requiring intensive care unit (ICU) admission. We aimed to assess survival of patients with a solid tumour admitted to ICU as an emergency with sepsis, and to identify predictors of 90-day survival at admission.Materials and MethodsWe conducted a retrospective cohort survival analysis. We identified adults with a solid tumour admitted to ICU with sepsis between 01/01/2011 and 31/12/2020 at a tertiary oncology centre with two hospitals (London and Surrey, UK). We defined sepsis using the Sepsis-3 definition. The primary outcome was 90-day survival. We used the parametric accelerated failure time model for multivariate analysis to generate acceleration factors (AF).Results625 patients were identified and the 90-day survival rate was 59.5%(353/593).Multivariate analysis identified the presence of localized (AF 0.13, 95% CI 0.06-0.25) or regionalized disease (AF 0.21, 95% CI 0.12-0.36) compared to distant metastatic disease, unplanned surgery on the day of admission (AF 0.15, 95% CI 0.07-0.31), lactate (AF 1.25 95% CI 1.15-1.35), Sequential Organ Failure Assessment Score (AF 1.19, 95% CI 1.12-1.27), previous radiotherapy (AF 1.89, 95% CI 1.14-3.125), previous systemic anti-cancer treatment (excluding hormonal therapy) (AF 1.49, 95% CI 0.93-2.38), bacteraemia (AF 0.47, 95% CI 0.27-0.81) and serum albumin (AF 0.94, 95% CI 0.91-0.98) as independent predictors of 90-day survival.ConclusionsThis study of solid tumour patients admitted to ICU is one of the largest providing survival data to inform clinicians and patients. This data provides information on factors that should be considered when deliberating the possible outcome of ICU admission for a patient with solid malignancy and sepsis and highlights that the presence of cancer itself should not limit ICU admission for sepsis.
引言
脓毒症是由宿主对感染的失调反应引起的危及生命的器官功能障碍。癌症患者有发生脓毒症并需要入住重症监护病房(ICU)的风险。我们旨在评估因脓毒症作为急诊入住ICU的实体瘤患者的生存率,并确定入院时90天生存率的预测因素。
材料和方法
我们进行了一项回顾性队列生存分析。我们确定了2011年1月1日至2020年12月31日期间在一家拥有两家医院(英国伦敦和萨里)的三级肿瘤中心因脓毒症入住ICU的成年实体瘤患者。我们使用脓毒症-3定义来定义脓毒症。主要结局是90天生存率。我们使用参数加速失效时间模型进行多变量分析以生成加速因子(AF)。
结果
共识别出625例患者,90天生存率为59.5%(353/593)。多变量分析确定,与远处转移性疾病相比,存在局限性(AF 0.13,95%CI 0.06 - 0.25)或区域性疾病(AF 0.21,95%CI 0.12 - 0.36)、入院当天的非计划手术(AF 0.15,95%CI 0.07 - 0.31)、乳酸(AF 1.25,95%CI 1.15 - 1.35)、序贯器官衰竭评估评分(AF 1.19,95%CI 1.12 - 1.27)、既往放疗(AF 1.89,95%CI 1.14 - 3.125)、既往全身抗癌治疗(不包括激素治疗)(AF 1.49,95%CI 0.93 - 2.38)、菌血症(AF 0.47,95%CI 0.27 - 0.81)和血清白蛋白(AF 0.94,95%CI 0.91 - 0.98)是90天生存率的独立预测因素。
结论
这项对入住ICU的实体瘤患者的研究是提供生存数据以告知临床医生和患者的最大规模研究之一。这些数据提供了在考虑实体恶性肿瘤合并脓毒症患者入住ICU的可能结局时应考虑的因素信息,并强调癌症本身的存在不应限制因脓毒症入住ICU。